LFCR vs WST
LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry. WST: West Pharmaceutical Services provides essential high-quality, sterile packaging and delivery systems for injectable medications globally.
Side-by-side fundamentals
| Metric | LFCR | WST | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $4.43 | $355.48 | |
| Market cap as of 2026-07-24 | $171M | $25.7B | |
| P/E as of 2026-07-24 | n/a | 47.44 | |
| PEG as of 2026-07-24 | n/a | 3.24 | |
| Net margin as of 2026-07-24 | -26.5% | +16.9% | WST higher |
| Gross margin as of 2026-07-24 | +30.0% | +36.3% | WST higher |
| Operating margin as of 2026-07-24 | -1.9% | +20.3% | WST higher |
| ROE as of 2026-07-24 | -126.8% | +17.9% | WST higher |
| ROA as of 2026-07-24 | -18.9% | +13.2% | WST higher |
| Debt / equity as of 2026-07-24 | 7.16 | 0.07 | WST lower |
| Revenue growth (YoY) as of 2026-07-24 | +27.6% | +11.2% | LFCR higher |
| Revenue CAGR (3y) SEC XBRL | +5.3% | +2.1% | LFCR higher |
| Dividend yield as of 2026-07-24 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 1.13 | 1.12 | |
| 1-year return as of 2026-07-23 close | -41.2% | +56.4% | WST higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.